Induction therapy with rabbit anti-thymocyte globulin is preferable to induction with daclizumab in renal transplant recipients at high immunological risk. These findings provide additional support to ...

So in general, really blinatumomab was very well tolerated. There were some more cytopenias in some of the patients with ...

Approximately half of children with neuroblastoma reportedly have a form that indicates a high likelihood of recurrence. New findings “Efficacy of post-induction therapy for high-risk neuroblastoma ...

Adding a monoclonal antibody to standard three-drug induction therapy may offer a deeper response in newly diagnosed transplant-eligible patients with multiple myeloma, recent studies show. The ...

Approximately half of children with neuroblastoma - a childhood cancer that develops from immature nerve cells - have a form that indicates a high likelihood of recurrence. New findings published by ...

LONDON — With the availability of new potent immunosuppressive drugs for multiple sclerosis, a new hot topic discussion point in the field is whether these agents should be used as "induction therapy" ...

For younger, fit patients with mantle cell lymphoma (MCL), adding the Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib to standard induction therapy with bendamustine/rituximab followed by ...

Daily concurrent chemoradiotherapy with docetaxel (DOC) and cisplatin (CDDP) using superselective intra-arterial infusion via superficial temporal artery for T3 and T4 head and neck cancer: ...

Findings showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission, clinical response, and endoscopic improvement compared with placebo.

Please provide your email address to receive an email when new articles are posted on . The percentage of patients with clinical remission, evaluated with the three component Mayo score, served as the ...

Please provide your email address to receive an email when new articles are posted on . Encorafenib plus binimetinib induction did not confer a PFS benefit in advanced melanoma. Patients with high ...